Future of Care · Clinical Workflows

The Future of Insomnia Care—Scalable, Personalized, and Remote

The next generation of insomnia care should make evidence-based treatment easier to reach while preserving clinical assessment, patient choice, safety, and a clear path to higher-intensity care.

By Noctem Health Clinical Team · 9 min read

Updated on October 8, 2026

The future of insomnia care is unlikely to be a single app, device, medication, or algorithm. A more credible future is a coordinated service: people can enter care through familiar settings, receive cognitive behavioral therapy for insomnia (CBT-I) in a format they can use, and move to more or less intensive support according to response, preference, complexity, and risk. Digital tools can extend the reach of that service, but they do not remove the need for clinical judgment.

That distinction matters for health system leaders. Chronic insomnia is not simply a shortage of sleep that can be corrected by collecting more data. Diagnosis depends on a clinical history that considers the nighttime complaint, daytime consequences, opportunity for sleep, duration, medications and substances, other sleep disorders, and relevant medical and psychiatric conditions. The 2025 Department of Veterans Affairs and Department of Defense (VA/DoD) guideline notes that questionnaires can support screening but are not, by themselves, diagnostic.

The Clinical Foundation Should Not Change

Technology may change the route into care, but it should not displace the treatment with the strongest guideline support. The American Academy of Sleep Medicine (AASM) recommends multicomponent CBT-I for adults with chronic insomnia, and the 2025 VA/DoD guideline gives CBT-I a strong recommendation. The American College of Physicians likewise recommends CBT-I as the initial treatment for chronic insomnia in adults. These recommendations apply whether treatment is delivered in person, through telehealth, or with an evidence-based digital program.

CBT-I typically combines stimulus control, sleep restriction or sleep-compression procedures, cognitive strategies, and sleep education, often with relaxation or counter-arousal methods. Sleep hygiene can be useful as one component, but AASM and VA/DoD guidance advise against using sleep hygiene alone as treatment for chronic insomnia. A future-facing program that offers only generic tips, relaxation audio, or sleep tracking should not be represented as equivalent to CBT-I.

The goal is not to digitize every part of insomnia care. It is to make guideline-concordant care easier to enter, complete, monitor, and escalate when necessary.

From a Single Pathway to Stepped Care

A conventional specialty model asks nearly every patient to wait for the same scarce resource: a trained clinician delivering a full course of synchronous CBT-I. A stepped model starts with the least resource-intensive evidence-based option likely to be appropriate, measures response, and reserves specialist capacity for people who need it. Entry options may include brief behavioral treatment, guided digital CBT-I, group care, telehealth, or individual treatment. Stepped care is a service design, not a rule that everyone must begin with a self-guided app.

Digital CBT-I has a meaningful evidence base. A 2020 meta-analysis of randomized trials found benefits at the end of treatment and follow-up compared with control conditions. A 2022 network meta-analysis covering 54 randomized trials and 11,815 participants also found that several digital delivery approaches improved insomnia outcomes. Those findings support digital delivery as a legitimate route to CBT-I; they do not establish that every commercial sleep app is effective, that all formats perform equally for every patient, or that digital care eliminates noncompletion.

Direct evidence on triage is promising but still developing. In a 2024 randomized trial of 245 adults aged 50 and older, a strategy that used a checklist to allocate some participants to therapist-delivered CBT-I and switched digital nonresponders to therapist care produced greater reductions in insomnia severity and hypnotic use than an online-only strategy. The reported between-strategy effect sizes were small, and the study population limits broad generalization. It nevertheless illustrates an important principle: scalable care can conserve clinician time without treating self-guided care as a dead end.

Personalization Should Be Clinically Legible

Personalization is useful when the reason for a treatment decision can be explained. A patient who cannot safely tolerate a rapid reduction in time in bed may need a modified schedule and closer follow-up. A shift worker may need evaluation of circadian timing rather than progressively tighter sleep windows. Someone with possible obstructive sleep apnea needs an appropriate diagnostic pathway, while a person with bipolar disorder, seizure risk, substantial fall risk, or severe daytime sleepiness may require additional safeguards. These are clinical decisions, not merely opportunities for an algorithm to optimize engagement.

Patient preference is also part of personalization. Some people prefer self-directed treatment because it is private and flexible; others need language support, coaching, group accountability, or live therapy. A system can offer choices while maintaining fidelity to the active components of CBT-I. It should also make clear who reviews information, how quickly messages are addressed, and what patients should do in an urgent situation.

Where automation can help

• Score validated symptom measures and display change over time.
• Turn a daily sleep diary into interpretable weekly trends.
• Deliver structured lessons and reminders at the appropriate point in a treatment sequence.
• Identify missing data, worsening symptoms, or nonresponse for human review.
• Route routine education separately from questions that require a licensed clinician.

Automation becomes less defensible when it makes opaque diagnostic or treatment decisions, presents device estimates as facts, or generates alerts without an accountable response workflow.

If artificial intelligence is used, health systems still need defined intended use, validation in the populations served, monitoring for unequal performance, change control, privacy and security review, and a way for clinicians and patients to question its output. Novelty is not evidence of clinical benefit.

Remote Data Should Answer a Clinical Question

The sleep diary remains central to CBT-I because it captures the patient's estimate of bedtimes, sleep, awakenings, and out-of-bed times in a form that can guide behavioral treatment. Remote collection can reduce transcription and make trends visible between encounters. Standard symptom measures can complement the diary by showing whether perceived severity and daytime impact are changing.

Actigraphy and consumer wearables have narrower roles. The AASM conditionally suggests actigraphy for adults with insomnia when objective estimates are clinically useful, while emphasizing that it is not required for routine diagnosis. Consumer devices differ in sensors and algorithms and generally infer sleep rather than measure it directly. Their data may help discuss timing or variability, but disagreement between a wearable and a person's experience should prompt interpretation—not automatic intensification of treatment.

The risk is not only inaccurate data. Clinicians have described “orthosomnia,” in which an intense effort to perfect wearable sleep scores can precipitate sleep performance anxiety and reinforce worry and sleep-related preoccupation. The evidence began as a clinical case series rather than a prevalence study, so it should not be used to imply that tracking harms most patients. It does support a sensible design rule: collect the minimum data needed for a decision, explain its limitations, and allow tracking to be reduced when it becomes counterproductive.

Medication Still Requires Shared Decision-Making

Scalable behavioral care does not make medication irrelevant. The ACP guideline recommends discussing medication benefits, harms, and costs when CBT-I alone is unsuccessful and considering short-term use through shared decision-making. Choice depends on the symptom pattern, age, comorbidities, other medications, prior response, and patient priorities. Health systems should avoid automated continuation as well as abrupt, unsupported discontinuation—particularly for patients who have used sedative-hypnotic medicines for a long time.

The AASM's 2026 guideline on combining behavioral and pharmacologic therapies underscores how limited the evidence remains for many common sequencing decisions. The practical implication is humility: medication and CBT-I workflows should include reassessment, adverse-effect monitoring, and an individualized plan rather than a universal promise that digital treatment will eliminate medication use.

Scale Without Equity Is Not Access

A remote pathway can remove travel and scheduling barriers while creating others. Broadband, data plans, device ownership, digital literacy, disability access, language, work schedules, caregiving responsibilities, and trust all influence whether a person can participate. Completion rates among enrolled, digitally confident users do not reveal who never entered the pathway.

• Offer telephone, print, group, and synchronous options rather than making a smartphone the only door to care.
• Provide content in the languages patients use and test it with people who rely on screen readers, captions, keyboard navigation, or larger text.
• Measure referral, enrollment, completion, improvement, escalation, and dropout by relevant demographic and access variables.
• Design for low-bandwidth use and avoid requiring a consumer wearable unless it is clinically necessary.
• Create a human support route for account setup, diary completion, and treatment questions.

A Practical Roadmap for Health Systems

The safest way to build a future-ready insomnia service is to begin with a defined population and care gap, then connect technology to a complete clinical pathway. Purchasing software before assigning clinical ownership reverses that order.

1. Define the target population, entry criteria, exclusions, and the outcomes the service is expected to improve.
2. Map assessment, differential diagnosis, treatment choice, follow-up, escalation, medication coordination, and urgent-safety instructions.
3. Evaluate whether each intervention delivers evidence-based CBT-I components and whether supporting studies resemble the population and setting in which it will be used.
4. Assign responsibility for reviewing measures and messages, including coverage standards and maximum response times.
5. Set response and nonresponse criteria before launch, while preserving clinician override and patient choice.
6. Pilot with a manageable panel and examine clinical outcomes, treatment completion, adverse experiences, staff workload, wait time, reach, and equity.
7. Use the findings to refine staffing and thresholds before expansion; continue surveillance as the technology, content, or patient population changes.

Success should not be defined only by logins, modules completed, or data points collected. A balanced dashboard includes symptom response and remission, daytime functioning, patient experience and self-rated global improvement, access time, treatment completion, escalation, safety events, clinician workload, and differences in reach and outcome across groups. It should also track whether patients who do not improve actually reach the next level of care.

The future of insomnia care is not remote instead of relational. It is a system in which remote tools make evidence-based treatment more reachable, and relationships are available at the moments when judgment, adaptation, or support matter most.